naptumomab estafenatox
neotx
['naptumomab estafenatox']
neotx, the partner of active biotech developing naptumomab estafenatox, has presented new results from the phase i/iia trial at the aacr annual meeting 2023. redeye's analyst gives his comment: $acti 
A members network for financial professionals and private investors. We keep our eyes focused on Nordic Tech and Life Science based companies with global reach.